Document is current
Any future updates will be listed below
-
Authors
Vigo, Daniel V.
Hudec, Kristen L.
Ferdous, Saimoom
Munthali, Richard J.
Pei, Julia
Munro, Lonna
Pendakur, Krishna
Yatham, Lakshmi N.
Kessler, Ronald C.
Ng, Raymond T.
Puyat, Joseph H.
-
Funding
Funding for this research was provided by:
Canadian Institutes of Health Research (173096)
- License Information
-
More Information
Article History
Received: 26 October 2023
Accepted: 4 February 2025
First Online: 22 February 2025
Declarations
:
: This study was performed using de-identified data routinely collected as part of public health surveillance and/or routine healthcare encounters. As the study relies exclusively on the secondary use of non-identifiable information, patient consent was not required in accordance with the Canadian Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans– TCPS 2 (2022), Article 5.5B. This study was reviewed and approved by the University of British Columbia Research Ethics Board (H20-02945) prior to initiation.
: Outside the submitted work, LY reports personal fees from Canadian Network for Mood & Anxiety Treatments, Gedeon Richter, Sanofi, Intracellular Therapies, Merck, and GSK; grants and personal fees from DSP and Abbvie; and, other financial activities from CANMAT and Alkermes. RK was a consultant for Datastat, Inc., Holmusk, RallyPoint Networks, Inc., and Sage Therapeutics, and he has stock options in Mirah, PYM, and Roga Sciences.
